MX2022004042A - Proteinas de union multiespecificas para tratamiento contra el cancer. - Google Patents
Proteinas de union multiespecificas para tratamiento contra el cancer.Info
- Publication number
- MX2022004042A MX2022004042A MX2022004042A MX2022004042A MX2022004042A MX 2022004042 A MX2022004042 A MX 2022004042A MX 2022004042 A MX2022004042 A MX 2022004042A MX 2022004042 A MX2022004042 A MX 2022004042A MX 2022004042 A MX2022004042 A MX 2022004042A
- Authority
- MX
- Mexico
- Prior art keywords
- proteins
- binding proteins
- specific binding
- cancer treatment
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19201200 | 2019-10-02 | ||
| PCT/EP2020/077586 WO2021064137A2 (en) | 2019-10-02 | 2020-10-01 | Multi-specific binding proteins for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004042A true MX2022004042A (es) | 2022-05-02 |
Family
ID=68136317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004042A MX2022004042A (es) | 2019-10-02 | 2020-10-01 | Proteinas de union multiespecificas para tratamiento contra el cancer. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11732045B2 (https=) |
| EP (1) | EP4038100A2 (https=) |
| JP (2) | JP7387885B2 (https=) |
| KR (1) | KR20220075383A (https=) |
| CN (1) | CN114641496B (https=) |
| AR (1) | AR120138A1 (https=) |
| AU (1) | AU2020358893A1 (https=) |
| BR (1) | BR112022004047A2 (https=) |
| CA (1) | CA3153372A1 (https=) |
| CL (1) | CL2022000664A1 (https=) |
| CO (1) | CO2022003552A2 (https=) |
| CR (1) | CR20220136A (https=) |
| DO (1) | DOP2022000060A (https=) |
| EC (1) | ECSP22019193A (https=) |
| IL (1) | IL291817A (https=) |
| JO (1) | JOP20220079A1 (https=) |
| MX (1) | MX2022004042A (https=) |
| MY (1) | MY209387A (https=) |
| PE (1) | PE20221412A1 (https=) |
| PH (1) | PH12022550693A1 (https=) |
| SA (1) | SA522432139B1 (https=) |
| TW (1) | TWI878355B (https=) |
| UA (1) | UA130106C2 (https=) |
| WO (1) | WO2021064137A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| CN114395043B (zh) * | 2021-12-07 | 2023-07-11 | 合肥天港免疫药物有限公司 | Ncr3lg1抗体及其应用 |
| CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| CN114395045B (zh) * | 2021-12-07 | 2023-06-09 | 合肥天港免疫药物有限公司 | B7h6抗体及其应用 |
| WO2024089006A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| CA3266173A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING |
| JP2026512969A (ja) | 2022-10-26 | 2026-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇを活性化することができる複素環式化合物 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731A (en) | 1848-08-22 | Elisha k | ||
| US168A (en) | 1837-04-17 | Improvement in fire-arms | ||
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69305085D1 (de) | 1992-08-10 | 1996-10-31 | Alcan Aluminium Ltd | Geländer |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| RU2420537C2 (ru) | 2001-01-17 | 2011-06-10 | Трабьон Фармасьютикалз Инк. | Слитые белки связывающий домен-иммуноглобулин |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| NL1019562C2 (nl) | 2001-12-13 | 2003-06-17 | Heineken Tech Services | Klepsamenstel voor gebruik bij drankafgifte. |
| US8764654B2 (en) | 2008-03-19 | 2014-07-01 | Zin Technologies, Inc. | Data acquisition for modular biometric monitoring system |
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| CN102099055A (zh) | 2007-10-04 | 2011-06-15 | 津莫吉尼蒂克斯公司 | B7家族成员zB7H6及相关的组合物和方法 |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| FI20090280A7 (fi) | 2009-07-17 | 2011-01-18 | Kone Corp | Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa |
| KR101721187B1 (ko) | 2009-12-23 | 2017-03-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 면역원성의 감소 방법 |
| KR102060389B1 (ko) * | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| AU2012323287B2 (en) * | 2011-10-10 | 2018-02-01 | Xencor, Inc. | A method for purifying antibodies |
| WO2013169691A1 (en) * | 2012-05-07 | 2013-11-14 | Trustees Of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
| IN2015DN01299A (https=) * | 2012-07-23 | 2015-07-03 | Zymeworks Inc | |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2017181001A1 (en) * | 2016-04-15 | 2017-10-19 | Trustees Of Dartmouth College | High affinity b7-h6 antibodies and antibody fragments |
| RS61510B1 (sr) | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anti pd-1 i anti-lag3 antitela za lečenje kancera |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
-
2020
- 2020-09-30 TW TW109134076A patent/TWI878355B/zh active
- 2020-10-01 MX MX2022004042A patent/MX2022004042A/es unknown
- 2020-10-01 JP JP2022520371A patent/JP7387885B2/ja active Active
- 2020-10-01 MY MYPI2022001742A patent/MY209387A/en unknown
- 2020-10-01 UA UAA202201295A patent/UA130106C2/uk unknown
- 2020-10-01 PH PH1/2022/550693A patent/PH12022550693A1/en unknown
- 2020-10-01 IL IL291817A patent/IL291817A/en unknown
- 2020-10-01 AU AU2020358893A patent/AU2020358893A1/en active Pending
- 2020-10-01 PE PE2022000468A patent/PE20221412A1/es unknown
- 2020-10-01 KR KR1020227014608A patent/KR20220075383A/ko active Pending
- 2020-10-01 EP EP20789508.7A patent/EP4038100A2/en active Pending
- 2020-10-01 AR ARP200102733A patent/AR120138A1/es unknown
- 2020-10-01 WO PCT/EP2020/077586 patent/WO2021064137A2/en not_active Ceased
- 2020-10-01 BR BR112022004047A patent/BR112022004047A2/pt unknown
- 2020-10-01 US US17/060,111 patent/US11732045B2/en active Active
- 2020-10-01 CR CR20220136A patent/CR20220136A/es unknown
- 2020-10-01 CA CA3153372A patent/CA3153372A1/en active Pending
- 2020-10-01 CN CN202080068909.4A patent/CN114641496B/zh active Active
-
2022
- 2022-01-31 JO JOP/2022/0079A patent/JOP20220079A1/ar unknown
- 2022-03-14 EC ECSENADI202219193A patent/ECSP22019193A/es unknown
- 2022-03-18 DO DO2022000060A patent/DOP2022000060A/es unknown
- 2022-03-18 CL CL2022000664A patent/CL2022000664A1/es unknown
- 2022-03-25 CO CONC2022/0003552A patent/CO2022003552A2/es unknown
- 2022-03-31 SA SA522432139A patent/SA522432139B1/ar unknown
-
2023
- 2023-06-20 US US18/337,693 patent/US20230340130A1/en active Pending
- 2023-11-15 JP JP2023194494A patent/JP7809680B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4038100A2 (en) | 2022-08-10 |
| US11732045B2 (en) | 2023-08-22 |
| AR120138A1 (es) | 2022-02-02 |
| SA522432139B1 (ar) | 2024-08-29 |
| US20230340130A1 (en) | 2023-10-26 |
| PH12022550693A1 (en) | 2023-03-27 |
| CN114641496B (zh) | 2026-01-02 |
| CR20220136A (es) | 2022-05-27 |
| PE20221412A1 (es) | 2022-09-20 |
| MY209387A (en) | 2025-07-07 |
| CA3153372A1 (en) | 2021-04-08 |
| TW202128756A (zh) | 2021-08-01 |
| CL2022000664A1 (es) | 2023-01-06 |
| KR20220075383A (ko) | 2022-06-08 |
| IL291817A (en) | 2022-06-01 |
| ECSP22019193A (es) | 2022-04-29 |
| JP2022551081A (ja) | 2022-12-07 |
| JOP20220079A1 (ar) | 2023-01-30 |
| US20210107983A1 (en) | 2021-04-15 |
| JP7387885B2 (ja) | 2023-11-28 |
| BR112022004047A2 (pt) | 2022-05-24 |
| JP2024020414A (ja) | 2024-02-14 |
| JP7809680B2 (ja) | 2026-02-02 |
| WO2021064137A2 (en) | 2021-04-08 |
| UA130106C2 (uk) | 2025-11-12 |
| TWI878355B (zh) | 2025-04-01 |
| DOP2022000060A (es) | 2022-05-31 |
| WO2021064137A3 (en) | 2021-05-14 |
| CO2022003552A2 (es) | 2022-04-19 |
| CN114641496A (zh) | 2022-06-17 |
| AU2020358893A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004042A (es) | Proteinas de union multiespecificas para tratamiento contra el cancer. | |
| CO2018012374A2 (es) | Moléculas de anticuerpo para el tratamiento del cáncer | |
| JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| MX2019006727A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| UY38242A (es) | Anticuerpos anti-cd33, anticuerpos bioespecíficos anti- cd33/anti-cd3 y usos de éstos | |
| EA202090817A1 (ru) | Триспецифические белки и способы их применения | |
| MX2019006724A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| EP4378962A3 (en) | Anti-cancer fusion polypeptide | |
| BR112017010110A2 (pt) | anticorpos contra cd73 e usos do mesmo | |
| MX2020011914A (es) | Anticuerpos anti-dll3 y usos de los mismos. | |
| MY200710A (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| MX2019014397A (es) | Polipeptidos que enlazan adamts5, mmp13 y agrecano. | |
| MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. | |
| MX2020001287A (es) | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. | |
| CL2019003074A1 (es) | Variantes de la proteína bmp7 humana. | |
| MX2024003615A (es) | Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3). | |
| WO2022236276A3 (en) | Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof | |
| WO2021043810A8 (en) | Anti-fucosyl-gm1 antibodies | |
| AR115506A1 (es) | Proteínas de fijación multiespecífica para el tratamiento del cáncer | |
| CO2019006926A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
| EA202193035A1 (ru) | Материалы и способы для модуляции иммунитета, опосредованного т-клетками |